Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01385748 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Clonidine Lauriad® to Treat Oral Mucositis
A Phase 2 study, sponsored by Valerio Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 183
- Enrollment target
NCT01385748 is a Phase 2 study that has completed, run by Valerio Therapeutics. The registered enrollment target is 183 participants.
The verdict
NCT01385748, a Phase 2 study, has completed, sponsored by Valerio Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 183 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of Clonidine Lauriad® to treat chemoradiation therapy induced severe oral mucositis in patients with head and neck cancer.
Interventions
- DRUG Clonidine Lauriad® 50µg
- DRUG Clonidine Lauriad® 100µg
- DRUG Placebo Lauriad®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2010-04 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01385748
The ClinicalTrials.gov registry entry for NCT01385748 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Valerio Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Clonidine Lauriad® 50µg is the first listed.
NCT01385748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01385748 about?
NCT01385748 is a clinical study titled "Efficacy and Safety Study of Clonidine Lauriad® to Treat Oral Mucositis". The purpose of this study is to evaluate the efficacy and safety of Clonidine Lauriad® to treat chemoradiation therapy induced severe oral mucositis in patients with head and neck cancer.
What is the current status of trial NCT01385748?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 183 participants. The study started on 2010-04. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01385748?
The interventions under investigation include: Clonidine Lauriad® 50µg (DRUG), Clonidine Lauriad® 100µg (DRUG), Placebo Lauriad® (DRUG).
Who is sponsoring clinical trial NCT01385748?
This trial is sponsored by Valerio Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.